AUS
NZ
UK
CA
USA
IND
Highlights:
- BioVaxys raises $225,000 through the issuance of 4.5 million units in a non-brokered private placement.
- The funds will support advancing the company's innovative oncology and immunological development portfolio.
- 1.53 million shares were issued to settle debt, reinforcing the company's financial strategy.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) has recently completed the fifth tranche of its non-brokered private placement, successfully raising $225,000 by issuing 4.5 million units priced at $0.05 each. Each unit comprises one common share and a warrant, allowing investors to acquire additional shares at $0.15 until October 4, 2026. This latest round of financing underscores BioVaxys's commitment to enhancing its research and development capabilities, particularly in oncology and immunology.
The proceeds from this private placement will primarily be allocated towards general working capital. A significant focus will be on propelling forward the company's ambitious business plans, particularly following its recent acquisition of an extensive portfolio of preclinical and clinical assets. These assets leverage the innovative DPX™ immune educating platform technology, originally developed by the now-defunct Canadian biotech firm, IMV Inc.
BioVaxys's acquisition from IMV USA on February 16, 2024, marks a pivotal moment for the company, providing it with a robust foundation to advance its clinical research initiatives. The DPX™ platform is designed to harness the body’s immune response to combat various diseases, including cancer and infectious diseases. By integrating this technology, BioVaxys aims to position itself as a leader in the immunotherapy landscape.
Additionally, the company has taken steps to strengthen its financial position through a debt settlement arrangement. BioVaxys issued 1,532,500 shares at a deemed price of $0.05 per share, effectively settling $76,625 in obligations to a consultant. This move not only alleviates debt but also aligns with the company’s strategic objectives, ensuring that financial resources are directed towards growth and development.
All securities issued during this tranche are subject to a statutory hold period, which will expire on February 5, 2025, adhering to applicable securities legislation. Importantly, these securities have not been registered under the United States Securities Act and cannot be offered or sold in the U.S. without compliance with the registration requirements or available exemptions.
As BioVaxys continues to navigate the complexities of the biotech sector, its recent funding initiatives reflect a proactive approach to securing the necessary capital to foster innovation. The commitment to the DPX™ platform is particularly noteworthy, as it represents a significant leap forward in the company's quest to develop effective treatments for critical health challenges.
